Naivek Announces Research Results on Pulmonary Fibrosis Treatment at Bio USA

[Asia Economy Reporter Jang Hyowon] Nivek announced on the 7th that it has been invited to the '2022 BIO International Convention (hereinafter BIO USA)' to present its major pipelines and conduct business partnering. BIO USA is the world's largest biotech investment conference, held from the 13th to the 16th local time. Nivek has been selected as a presentation company.

This year, BIO USA is being held offline for the first time since COVID-19, with a total of 210 companies giving presentations. From Korea, a total of 20 companies, including 6 listed companies and 14 unlisted companies, including Nivek, are participating.

On the 13th, Nivek will conduct a Company Presentation and plans to continue related discussions such as licensing out through one-on-one partnering with global pharmaceutical companies over four days.

At this conference, Nivek will present its major business strategies including its proprietary R&D programs: △ pulmonary fibrosis treatment ‘NIPEP-PF’ △ inflammatory bowel disease treatment ‘NIPEP-IBD’ △ K-RAS inhibitor anticancer treatment ‘NIPEP-TPP-K-RAS’ △ blood-brain barrier (BBB) penetrating delivery system ‘NIPEP-TPP-BBB Shuttle’.

In particular, Nivek will share its research achievements and clinical plans for the pulmonary fibrosis treatment, which is on the verge of entering global Phase 1 clinical trials. In addition, business partnering meetings are scheduled based on research achievements related to major development projects such as the NIPEP-TPP-BBB Shuttle, the anticancer pipeline applying the selective permeability drug delivery platform ‘NIPEP-TPP’, and the inflammatory bowel disease treatment.

A company official said, “Being selected as a presenting company at BIO USA, which is held fully offline for the first time since COVID-19, will allow us to discuss core pipelines with global big pharma.” He added, “Since detailed coordination is possible during partnering meetings when selected as a presenting company, we will achieve technology-related results through in-depth discussions.”

He continued, “BIO USA is an international event with about 8,000 participating companies before COVID-19, so through face-to-face company presentations and partnering meetings, we will seek concrete commercialization opportunities such as joint research and technology export with global pharmaceutical companies.”

Meanwhile, Nivek has completed contracts with a global clinical research organization (CRO) for conducting Phase 1 clinical trials of the pulmonary fibrosis treatment NIPEP-PF in Australia and has finished consultations with clinical trial hospitals.

This content was produced with the assistance of AI translation services.